Celgene's Psoriasis Drug Still Doesn't Impress NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, is sticking to its guns and not recommending Celgene Corporation's Otezela (apremilast) for use on the UK's National Health Service.